Find an Alzheimer's clinical trial

If you are thinking about joining a trial

A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.

Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.

Search title, drug, condition or sponsor

Recruiting

Exact registry status

Phase

Intervention class

Study type

Country

Results per page

Clear filters Download all 7,816 as CSV

"Open to new participants" means the registry status is RECRUITING or NOT_YET_RECRUITING — 1,523 of the 7,816 records. That is what the sponsor last told the registry, which can be months out of date.
Location is by country. This pull of the registry records the countries a study runs in, not its individual sites, so we cannot filter by US state or city — and we are not going to guess one. To find the nearest site, open a trial's record below: the official page lists every location with its contact details.

Showing 7,401–7,425 of 7,816 matching trials · page 297 of 313, 25 per page.

Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.

Registered Alzheimer's clinical trials. Every ID links to its official ClinicalTrials.gov record.
Trial	Phase	Status	Enrolled	Sponsor	Last updated
Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients NCT00503516 Megestrol acetate; Placebo Runs in: Spain · 1 site	PHASE2\|PHASE3 other	TERMINATED	39	Rottapharm Spain INDUSTRY	2011-06-08
Escitalopram and Depression in Elderly Alzheimer's Patients NCT00488670 Escitalopram Runs in: Canada · 2 sites	PHASE3 other	TERMINATED	50	University of British Columbia OTHER	2011-06-06
Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders NCT01143350 Bras A (EHPAD Training and stimulation); EHPAD Control Runs in: France · 1 site	NA other	TERMINATED	300	Centre Hospitalier Universitaire de Nice OTHER	2011-06-01
Study of Magnetic Fields to Treat Alzheimer's Disease NCT01313806 Resonator; Placebo Runs in: United States · 2 sites	NA other	WITHDRAWN	30	pico-tesla Magnetic Therapies, LLC INDUSTRY	2011-05-30
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease NCT00287742 risperidone	PHASE3 other	TERMINATED	33	Janssen Pharmaceutical K.K. INDUSTRY	2011-05-24
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation NCT00253214 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	973	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-23
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease NCT00082602 galantamine ER	PHASE3 symptomatic-cholinergic	COMPLETED	83	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-20
A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease NCT00645190 Galantamine HBr	PHASE3 symptomatic-cholinergic	COMPLETED	215	Xian-Janssen Pharmaceutical Ltd. INDUSTRY	2011-05-19
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia NCT00210769 paliperidone ER Oros	PHASE3 other	COMPLETED	203	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment NCT00240695 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	724	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease NCT00253188 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	653	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease NCT00253201 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	636	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease NCT00253227 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	387	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia NCT00261573 galantamine hydrobromide	PHASE3 symptomatic-cholinergic	COMPLETED	593	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease. NCT00309725 galantamine	PHASE3 symptomatic-cholinergic	COMPLETED	139	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. INDUSTRY	2011-05-18
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease. NCT00301574 galantamine	PHASE3 symptomatic-cholinergic	COMPLETED	398	Janssen Pharmaceutical K.K. INDUSTRY	2011-05-17
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease NCT01125683 AZD1446; Donepezil; Placebo Runs in: Russia; Ukraine · 7 sites	PHASE2 symptomatic-cholinergic	TERMINATED	40	AstraZeneca INDUSTRY	2011-05-13
Exercise Treatment of Mild-Stage Probable Alzheimer's Disease NCT00403507 Participation in a monitored exercise program; Personalized aerobic... Runs in: United States · 1 site	PHASE2 other	COMPLETED	79	Intermountain Health Care, Inc. OTHER	2011-05-11
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex NCT00002246 Stavudine Runs in: Australia; United Kingdom; United States · 5 sites	PHASE3 other	COMPLETED	20	Bristol-Myers Squibb INDUSTRY	2011-05-04
Predictors of Neuro-cognitive Decline and Survival in HIV-infected Subjects NCT00864292 Runs in: Thailand · 1 site	NA other	COMPLETED	60	SEARCH Research Foundation OTHER	2011-05-03
Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home NCT01314131 Stimulation group Runs in: France · 1 site	NA other	UNKNOWN	48	Association Recherche Méthodologie Evaluation Psychiatrique OTHER	2011-04-29
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets NCT01089582 No intervention Runs in: Greece · 29 sites	NA other	COMPLETED	628	Pfizer INDUSTRY	2011-04-28
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects NCT00825084 Dimebon; Dimebon; Dimebon; Dimebon Runs in: United States · 1 site	PHASE1 other	COMPLETED	45	Pfizer INDUSTRY	2011-04-26
Copy Number Variations, Inflammatory Cytokines and the Risk of Dementia NCT00878280 Runs in: Taiwan · 1 site	NA other	UNKNOWN	700	National Taiwan University Hospital OTHER	2011-04-22
Effects of rTMS on the Cognition of Elderly With Mild Memory Complaints NCT01292382 Repetitive transcranial magnetic stimulation; Repetitive transcrani... Runs in: Brazil · 1 site	NA other	UNKNOWN	34	University of Sao Paulo General Hospital OTHER	2011-04-21

This table is wider than a phone screen — swipe it sideways to see the rest.

Where these trials come from

Registry: ClinicalTrials.gov, pulled through their public API (v2)
Trials in the file: 7,816
Source file: trials.csv (3.8 MB, 7816 rows)
Basis: Measured These are registry records as submitted by each study's sponsor.

What could make this misleading

Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.

Always check the official record before acting on anything here. This is a summary, not medical advice.

From the research library

The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.

Clinical trials

MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024 · score 88/100
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet. Neurology, 2026 · score 86/100
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2021 · score 86/100
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease Journal of Alzheimer's disease : JAD, 2026 · score 86/100
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial EBioMedicine, 2024 · score 85/100

All 162 studies on Clinical trials →